disease may vary, depending on factors like genotype, gender and still as yet unknown genetic modifiers. More knowledge concerning genetic variations and their clinical and therapeutic correlates is needed. Accumulation of GL3 starts early in Fabry disease and classically affected individuals suffer neuropathic pain from childhood. The natural history of Fabry disease includes chronic renal disease, cardiomyopathy, cerebrovascular disease and premature death [3] [4] [5] [6] .
Enzyme replacement therapy (ERT) has greatly improved the quality of life for many Fabry patients [7] [8] [9] and has been found to ameliorate Fabry nephropathy, particularly in younger patients [10] [11] [12] [13] . However, the effects of ERT on Fabry cardiomyopathy and cerebrovascular disease may be more tenuous [14] .
Agalsidase-a 0.2 mg/kg every other week (eow) and agalsidase-b 1.0 mg/kg/eow were licensed in Europe in 2001. A global shortage of agalsidase-b between 2009 and 2012 caused many patients worldwide to be switched from agalsidase-b to agalsidase-a [15] . Clinical and surrogate biomarker findings related to the switch between agalsidase-a and -b therapy suggest different effects of the respective licensed doses [16, 17] . Studies comparing the two products have reported that the two licensed doses may not be equipotent either in vivo [13, [16] [17] [18] or in vitro [19, 20] . Associated renal biopsy findings have not been studied, and after nearly 15 years of clinical use and research, the question of dose equipotency is still highly relevant. This case series presents the three treatment-naïve patients with classical Fabry disease in our centre started on agalsidase-b 1.0 mg/ kg/eow and switched to agalsidase-a 0.2 mg/kg/eow due to the global shortage. Baseline and 5-year data from these patients were previously published by Tøndel et al. [4, 13] . Additional biopsy data collected after the switch from agalsidase-b 1.0 mg/ kg/eow to agalsidase-a 0.2 mg/kg/eow are presented in this case series.
M A T E R I A L S A N D M E T H O D S
At our centre, Fabry patients routinely undergo baseline and follow-up kidney biopsies to assess kidney damage prior to ERT and subsequent disease course and treatment effect, according to a clinical research protocol approved by the regional ethics committee. Three patients whose primary ERT was agalsidaseb 1.0 mg/kg/eow were switched to agalsidase-a 0.2 mg/kg/eow in our centre, all of whom were included in this case series. Informed consent was signed in all cases. The patients were diagnosed with classical Fabry disease (missense mutation M267R) as a consequence of family screening and started agalsidase-b 1.0 mg/kg/eow at the ages of 7, 11 and 18 years, respectively. All had severe Fabry-associated acral pain, gastrointestinal manifestations and minor albuminuria. Brain MRI showed white matter lesions in two patients. None had cardiac manifestations. Kidney biopsies were performed with real-time ultrasound-guided automated technique. The biopsies were scored according to the scoring system of the International Scoring Group of Fabry Nephropathy (ISGFN) [21] by an experienced renal pathologist who was blinded with respect to treatment. Podocyte GL3 inclusions and vacuolizations were scored in toluidine blue-stained semi-thin sections (score 0-4) and periodic acid-Schiff-stained paraffin sections (score 0-3), respectively. To increase representativity, podocyte inclusion and vacuolization scores were combined to a composite score with a maximum of 7.0 [13] . Glomerular filtration rate (GFR) was measured by iohexol plasma clearance, normalized to body surface area in mL/min/1.73 m 2 [22] . Albuminuria was defined as an albumin:creatinine ratio >2.5 mg/mmol creatinine. IgG antibodies to agalsidase were analysed at Sahlgrenska University Hospital, Sweden, and compared to a pool of 50 healthy blood donors. A quota of <2.5 was considered negative.
R E S U L T S

Patient 1
Patient 1 was diagnosed with Fabry disease at 5 years of age. He suffered from severe Fabry-associated acral pain, abdominal pain, diarrhoea and hypohidrosis. Analgesics were prescribed for approximately half a year prior to initiation of agalsidase-b 1.0 mg/kg/eow and were discontinued after 2 months of ERT. After 3 years of ERT his pain recurred, and analgesics were reinstated. Sudden unilateral deafness occurred after 3.5 years of ERT. He was rebiopsied after 5 years of agalsidase-b 1.0 mg/kg/eow. Marked clearing of GL3 from the podocytes was seen, as the composite podocyte score decreased from 7.0 at baseline to 0.4 at Year 5 ( Table 2) (Figures 1 and 2 ). Mesangial and endothelial cells were completely cleared of GL3 deposits [13] . Due to the global shortage of agalsidase-b, he was switched to agalsidase-a 0.2 mg/kg/eow after 5 years of ERT. During the first 7 months of agalsidase-a he had several Fabry crises, and Fabry-associated acral pain persisted in the face of analgesics. After 8 years of ERT, 5 years of agalsidase-b and 3 years of agalsidase-a, albuminuria and microscopic haematuria occurred. Renal histology was consistent with post-infectious glomerulonephritis. The podocytes were normal. The composite podocyte GL3 score increased from 0.4 at Year 5 to 1.3 at Year 8 (Table 2) , indicating a reaccumulation of GL3 after 3 years on the lower dose of ERT. As agalsidase-b was again globally available at this time point, the patient was reswitched to agalsidaseb. Two years after the reswitch to agalsidase-b 1.0 mg/kg/eow, persisting albuminuria and a marked decrease in measured GFR as compared with baseline necessitated a fourth kidney biopsy. A renewed decrease in the podocyte composite score (from 1.3 to 0.6) was observed 2 years after agalsidase-b 1.0 mg/ kg/eow was reinstated, indicating increased clearance of podocyte GL3 deposits due to the increased agalsidase dose. Histology was also consistent with a chronic post-infectious glomerulonephritis, with segmental fusion of the foot processes.
Patient 2
Patient 2 was diagnosed with Fabry disease at 9 years of age. She suffered from Fabry-associated acral pain, abdominal pain, headaches and hypohidrosis. Analgesic treatment was started 18 months prior to initiation of agalsidase-b 1.0 mg/kg/eow and discontinued after only a few infusions of agalsidase. She received agalsidase-b 1.0 mg/kg/eow for 5 years, with adequate
She was rebiopsied after 5 years of ERT and a decrease in composite podocyte score from 7.0 at baseline to 2.9 (Table 2) was observed. Mesangial and endothelial cells were completely cleared of GL3 deposits [13] . When the global shortage of agalsidase-b occurred, ERT was discontinued. During a 7-month treatment hiatus, she had a relapse of Fabry-associated acral pain, abdominal cramps with diarrhoea, tiredness and headaches. Agalsidase-a 0.2 mg/kg/eow was given the next 2 years and 5 months, followed by a kidney biopsy. The podocyte GL3 score increased from 2.9 after 5 years of high-dose ERT to 4.0 after 3 years of no or low-dose ERT (Figure 1) . The foot processes were normal. Kidney function remained normal without albuminuria. Inadequate symptom relief was reported on the lower dose of ERT. She was switched back to agalsidase-b 1.0 mg/kg/eow after this biopsy, as the product was again available.
Patient 3
Patient 3 was diagnosed with Fabry disease at 18 years of age. He had suffered Fabry-associated acral pain since the age of 5 years, including severe Fabry crises. He also had gastrointestinal symptoms and hypohidrosis. Daily analgesic treatment was started at diagnosis and a significant reduction of Fabryassociated acral pain was reported after 3 months of agalsidaseb 1.0 mg/kg/eow. After 1 year of ERT, albuminuria decreased (Tables 1 and 3 ) and measured GFR remained stable. He was rebiopsied after 1 year of ERT. The composite podocyte score remained unchanged at 7.0. However, mesangial and endothelial cells were completely cleared of GL3 deposits [13] . After 5 years of agalsidase-b 1.0 mg/kg/eow, clinical and biochemical parameters remained stable, the composite podocyte score decreased from 7.0 at baseline to 4.9 at Year 5 and the foot processes were normalized (Table 2) [13] . Due to the global Table 3 ). The follow-up kidney biopsy showed reaccumulation of podocyte GL3 deposits. The composite podocyte score increased from 4.9 after 5 years of agalsidase-b 1.0 mg/kg/eow to 5.9 after 13 months of agalsidase-b 0.5 mg/kg/eow followed by 2 years of agalsidase-a 0.2 mg/kg/eow. The foot processes did not change 
D I S C U S S I O N
To our knowledge, this is the first report of morphologic renal findings associated with dose switches undertaken in the ERT shortage period 2009-12. We present three young patients with classical Fabry disease who, over a treatment period of 8-10 years, received both agalsidase-a and agalsidase-b in licensed doses. Partial clearing of podocyte GL3 deposits was found in all three patients on the higher dose of agalsidase after 5 years of ERT. Subsequent kidney biopsies showed the agalsidase dose affected the level of GL3 clearance from podocytes, as evidenced by the accompanying change in composite podocyte score seen as the agalsidase dose was decreased and increased. A consistent increase in clinical symptoms paralleled the morphologic deterioration in all patients, an observation that further adds to the recently reported associations between dose changes and clinical deterioration [16, 17] . Of note, ERT dose reduction did not cause GL3 reaccumulation in mesangial and endothelial cells, which were parameters used in clinical trials during the licensing process [10, 23] .
Najafian et al. [24] previously described progressive accumulation of podocyte GL3 deposits with increasing age in children and young adults, in contrast to mesangial and endothelial cells where accumulation was found to be age and sex independent. In the current case series, all three patients had full composite podocyte GL3 scores prior to ERT; GL3 deposits were also seen in the mesangial and endothelial cells. Follow-up kidney biopsies after 5 years of agalsidase-b 1.0 mg/kg/eow revealed partial clearing of GL3 from the podocytes and total clearing of the mesangium and endothelium. The comparatively better clearance observed in the two patients who started ERT at the ages of 7 and 11 years, respectively, may be due to initiation of ERT at a younger age.
During the global shortage of agalsidase-b, patients worldwide had to be switched to agalsidase-a 0.2 mg/kg/eow [15] . Our findings of reaccumulation of podocyte GL3 on the lower agalsidase dose (Figure 1 ) support previously published reports suggesting that the products have the same effect, milligram for milligram, whether in vitro [19, 20] or in vivo [13, [16] [17] [18] . Podocyte reaccumulation seemed to occur at the same rate in all three patients, although Patient 2 had been without ERT for 7 months and Patient 3 received agalsidase-b 0.5 mg/kg/eow for a period of 13 months before the switch to agalsidase-a 0.2 mg/ kg/eow. No reaccumulation of GL3 was seen in mesangial or endothelial cells, indicating that the lower dose was sufficient to avoid GL3 reaccumulation in these cells. This corresponds to findings from Lubanda et al. [25] , who described maintained clearing of most kidney cells in patients switched to agalsidaseb 0.3 mg/kg/eow after first receiving 1.0 mg/kg/eow for 6 months, as well as earlier findings from our group [13] . Foot process effacement decreased in all three patients after 5 years of agalsidase-b 1.0 mg/kg/eow [13] . Normalization of the foot processes was seen after an additional 3 years of ERT in the two patients without glomerulonephritis. This indicates that a lower dose may be sufficient to maintain beneficial effects on podocyte metabolism and repair of tissue damage. After 3 years of agalsidase-a 0.2 mg/kg/eow, measured GFR in Patient 3 had decreased by 18 mL/min/1.73 m 2 , with normalization after agalsidase-b 1.0 mg/kg/eow was reinstated (Figure 3 ). Albuminuria remained virtually unchanged (Table 3) . Our findings add to the recent observations of Lenders et al. [17] , reporting a significant drop in estimated GFR (eGFR) in patients who received a lower dose of agalsidase-b or were directly switched to agalsidase-a 0.2 mg/kg/eow. After 2 years of either reduced dose agalsidase-b or licensed dose agalsidase-a, eGFR fell significantly, while it remained stable in the group that continued to receive agalsidase-b 1.0 mg/kg/eow. Their patients were significantly older than the three patients described here, and a significant proportion had proteinuria at the time of inclusion, which in itself is known to be a risk factor for progressive kidney disease [26] . Lenders et al. [17] did not report kidney biopsies for any of the patients, and it is therefore uncertain to what degree the decrease in eGFR correlated with re-accumulation of GL3 in the kidneys. This, together with the findings in the present case series and the previously reported better clearing of GL3 from podocytes in young patients who received a higher cumulative dose of ERT [13] , argues for the two products being equipotent milligram for milligram for dose-dependent clinical effects. An increase in Fabry-related symptoms when the dose of ERT was reduced has previously been reported by Weidemann et al. [16] and Lenders et al. [17] . All three patients in the present case series reported an increase in Fabry-related symptoms as the ERT dose was reduced; the symptoms improved when the ERT dose was increased. Patient 1 underwent a kidney biopsy on clinical indication, i.e. unexpected decline in GFR, increasing albuminuria or unexplained haematuria, after a total ERT time of 10 years, 2 years after full-dose agalsidase-b was reinstated. Interestingly, the podocyte composite score decreased after reinstatement of fulldose agalsidase-b, clearly indicating improved clearance of GL3 on the higher dose of ERT (Figure 2 ). However, a diagnosis of chronic post-infectious glomerulonephritis was also made. These observations further underline the importance of rebiopsies in Fabry patients in order to establish a correct diagnosis when a clinical event occurs. Kidney biopsies are useful and safe [27] as a tool for evaluating the effect of ERT on Fabry nephropathy and in the diagnostic work-up of other causes of chronic kidney disease. The lack of kidney biopsies in most Fabry studies, including registries, may have resulted in an underestimation of the incidence of non-Fabry-related causes of progressive kidney disease. Kidney biopsies may also be useful in identifying individuals in whom maintenance of podocyte clearing is possible on a lower dose of agalsidase; such information is also highly relevant from a health-economy perspective.
The major limitation of this case series is the small number of investigated patients, who shared the same missense mutation. Podocyte scores increased in all three patients after 3 years of lower agalsidase dose; only one patient has thus far undergone a kidney biopsy after reinstatement of agalsidase-b 1.0 mg/kg/eow. The ISGFN scoring system [21] is semiquantitative and not unbiased as opposed to a morphometric approach [24] . It is validated and includes all scorable glomeruli in the biopsy, ensuring good representativity. It is also generally available, as it depends on light microscopy as opposed to electron microscopy.
In conclusion, we report the reduction, reaccumulation and renewed partial clearing of podocyte GL3 deposits in tandem with agalsidase dose adjustments assessed by serial kidney biopsies over 8-10 years. The observation further extends previously published results indicating that dose matters and underlines the importance of careful comprehensive individual disease and therapy assessments before irreversible kidney damage occurs [13, 16, 17, 28] .
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